GlassScriptPhysician profile
Mohammad Younus
NPI 1700114931
$1,913.99
in general payments reported to CMS, 2019-2025
24 companies · $418 in 2025
The $418 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.84 · 2020: $267 · 2021: $294 · 2022: $325 · 2023: $241 · 2024: $293 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $865 · Consulting Fee: $53.19 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $865.27 |
| Consulting Fee | $53.19 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $318.38 | 2019-2025 | Nucala |
| Pfizer INC. | $215.72 | 2019-2025 | |
| Leo Pharma INC. | $170.29 | 2022-2024 | Adbry |
| Regeneron Healthcare Solutions, INC. | $152.64 | 2019-2025 | Dupixent |
| Abbvie INC. | $128.23 | 2022-2024 | Rinvoq |
| Astrazeneca Pharmaceuticals LP | $117.76 | 2024 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $99.44 | 2019-2021 | |
| Genentech USA, INC. | $85.13 | 2021-2024 | Xolair |
| Optinose US, INC. | $71.98 | 2020-2024 | |
| Amgen INC. | $70.40 | 2025 | Actimmune, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $55.13 | 2020-2022 | |
| Adma Biomanufacturing LLC | $53.19 | 2025 | |
| Genzyme Corporation | $49.06 | 2023 | |
| Grifols USA, LLC | $46.16 | 2022 | |
| Octapharma USA, INC. | $42.13 | 2020-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $40.70 | 2021 | |
| Gc Biopharma USA, INC. | $36.13 | 2025 | Alyglo |
| Tersera Therapeutics LLC | $33.19 | 2021 | |
| Organon LLC | $33.00 | 2025 | Vtama |
| Pharming Healthcare, INC. | $28.39 | 2024 | Ruconest |
| Novartis Pharmaceuticals Corporation | $21.96 | 2024 | |
| Blueprint Medicines Corporation | $16.64 | 2022 | |
| Horizon Therapeutics Plc | $14.46 | 2022 | |
| Galderma Laboratories, L.P. | $13.88 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Younus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.